Evidence map›Paper›PMID 25232039›Full record

ReviewThe oncologist2014

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Charles J Ryan, Philip J Saylor, Jason J Everly, Oliver Sartor

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Review
  5. European journal of nuclear medicine and molecular imaging · 2018
    Article
  6. Review
  7. Article
  8. Radium-223 dichloride in clinical practice: a review.European journal of nuclear medicine and molecular imaging · 2016
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Charles J RyanDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA ryanc@medicine.ucsf.edu.
Philip J SaylorDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA.
Jason J EverlyDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA.
Oliver SartorDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA.
Harvard University · USTulane Medical Center · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical features of patients with castration-resistant prostate cancer (CRPC) are characterized by a high incidence of bone metastases, which are associated with impairment of quality of life, pain, skeletal-related events (SREs), and a negative impact on prognosis. Advances in the understanding of cancer cell-bone stroma interactions and molecular mechanisms have recently permitted the development of new agents. PURPOSE: We review the merits, applications, and limitations of emerging data sets on bone-metastatic CRPC with a focus on radium-223, an α-emitting radiopharmaceutical, and its use in therapy for this disease.

methodsReferences for this review were identified through searches of PubMed and Medline databases, and only papers published in English were considered. Related links in the databases were reviewed, along with relevant published guidelines, recently published abstracts from major medical meetings, and transcripts from a recent round table of clinical investigators.

resultsPrior to radium-223, available bone-targeted therapies demonstrated the ability to delay SREs and palliate bone pain in patients with metastatic CRPC but without evidence of improvement in overall survival (OS). In a randomized controlled phase III trial, radium-223 demonstrated the ability to improve OS and delay SREs in docetaxel-pretreated or docetaxel-unfit men with symptomatic bone-metastatic CRPC and was not associated with significantly more grade 3 or 4 adverse events than placebo.

conclusionRadium-223 has a targeted effect on bone metastases in CRPC and has an important role in docetaxel-pretreated or docetaxel-unfit men with symptomatic bone-metastatic CRPC.

Indexed as

Alpha ParticlesAntineoplastic AgentsBone and BonesBone Density Conservation AgentsBone NeoplasmsFractures, SpontaneousHumansMalePain ManagementProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsRadiumAntineoplastic AgentsBone Density Conservation AgentsRadioisotopesRadiopharmaceuticalsRadiumradium Ra 223 dichlorideBone-metastatic castration-resistant prostate cancerOverall survivalPainRadium-223Skeletal-related events

Identifiers

PMID25232039
PMCPMC4200991
OpenAlexW2134463877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.